Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2024-01-04 Regulatory Filings
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Regulatory Filings Classification · 95% confidence The document is a press release dated January 4, 2024, announcing significant clinical trial results (MAXA study) and two 510(k) clearances from the FDA for Kuros Biosciences' MagnetOs portfolio. This type of announcement, detailing key operational and product development milestones, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on preliminary study results and regulatory clearances rather than a full quarterly financial report (IR) or a transcript (CT), and it is a direct announcement of results rather than an announcement *about* a report (RPA), the most fitting category is Earnings Release (ER), as these often contain operational highlights alongside or instead of full financial tables. It is not a 10-K, AR, or IR. It is a direct announcement of results/advancements.
2024-01-04 English
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Regulatory Filings Classification · 99% confidence The document is identified as an 'Ad-hoc' announcement dated December 27, 2023, released pursuant to 'Art. 53 LR' (likely a Swiss regulatory requirement for ad-hoc disclosure). The content details the results from two clinical trials (STRUCTURE and MAXA) concerning the company's product, MagnetOs, and announces a strategic decision to discontinue development of Fibrin-PTH and focus resources on MagnetOs. This type of announcement, which discloses material, non-public information regarding clinical trial outcomes and strategic shifts, is typically classified as a general regulatory announcement or news release. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER), or a formal Investor Presentation (IP), and it is a direct disclosure of material information rather than just an announcement *about* a report (RPA), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for significant, non-standard disclosures not covered by other specific codes. The length (12,449 chars) confirms it is substantial content, not just a brief notice.
2023-12-27 English
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Regulatory Filings Classification · 95% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and announces clinical trial results (MAXA and STRUCTURE) and a strategic decision to discontinue development of Fibrin-PTH and focus on MagnetOs. This type of immediate, material information release, often mandated by listing rules (like the SIX Swiss Exchange's Art. 53 LR), is typically classified as a general regulatory announcement or a specific type of corporate action announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal proxy/voting document, and it is a direct announcement of material non-public information, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard corporate disclosures. It is too detailed to be a simple Report Publication Announcement (RPA).
2023-12-27 English
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Regulatory Filings Classification · 100% confidence The document is a press release dated November 28, 2023, announcing that Kuros Biosciences received FDA clearance for its MagnetOs product for use in interbody spinal cages. It details the significance of this regulatory approval, quotes the CEO, and provides contact information and boilerplate legal/company information. This type of announcement, focusing on a specific regulatory milestone (FDA clearance) that impacts commercial use, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to quarterly results, but since it is purely a regulatory/product update announcement, RNS is the most appropriate general category for significant, non-standard regulatory news that isn't a full financial report (10-K, IR, ER). Given the options, and since it's a specific regulatory event announcement rather than a financial report, RNS (Regulatory Filings/General Announcement) is the best fit, although it is highly specific news. It is not a Call Transcript (CT), Earnings Release (ER) (which focuses on financial results), or a Director's Dealing (DIRS). It is a news announcement about a regulatory event.
2023-11-28 English
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Regulatory Filings Classification · 100% confidence The document is a press release dated November 28, 2023, announcing that Kuros Biosciences received FDA clearance for its MagnetOs product for use in interbody spinal cages. This type of announcement, detailing a significant regulatory event (FDA clearance) and its commercial implications, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on a specific, positive regulatory milestone rather than comprehensive financial results (like a 10-K or IR) or a general update on management/dividends, it fits best as an Earnings Release (ER) which often includes key operational and regulatory achievements alongside financial highlights, or as a Regulatory Filing (RNS) if it were less focused on commercial impact. Given the structure and focus on a key operational/regulatory win, ER is a strong candidate, but RNS is the most appropriate fallback for specific, non-periodic regulatory news that isn't a formal SEC filing like 10-K or a specific announcement like DIV or DIRS. However, many companies use press releases for significant regulatory achievements, which often overlap with ER content. Since this is a specific regulatory approval announcement, and not a comprehensive financial report, RNS (Regulatory Filings/General Announcement) is the safest classification, as it is a specific regulatory event announcement that doesn't fit the other specific categories like DIV, DIRS, or 10-K. Given the options, RNS covers general regulatory news announcements well.
2023-11-28 English
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Earnings Release Classification · 95% confidence The document is an 'Ad-hoc' release dated October 12, 2023, providing an update on sales figures for the 'first nine months of 2023' (quarterly/interim performance highlights) and announcing significant changes in the Executive Management structure (CEO transition). The content includes key financial metrics (sales growth, EBITDA, cash position) typical of an earnings announcement, but it is presented as a brief update rather than a comprehensive report. Since it contains both financial highlights (suggesting ER or IR) and management changes (suggesting MANG), I must determine the primary focus. The document explicitly states it is a 'Release of an ad hoc announcement' and focuses heavily on the 9-month sales performance and the management transition. Given the dual nature, and the fact that it is a summary of period results rather than the full, detailed report, it aligns best with an Earnings Release (ER) which often includes operational highlights. However, the management change is a very prominent feature. If it were a full quarterly report, it would be 'IR'. Since it is a summary announcement of results and management changes, it fits the 'ER' category well, as it precedes a potential full report. The management change aspect points towards 'MANG', but the financial update for a nine-month period is substantial. In many regulatory contexts, an ad-hoc release combining financial highlights and management changes is often categorized based on the most significant driver or as a general regulatory filing. Since it provides key financial results for a period shorter than a year (9 months), 'IR' (Interim/Quarterly Report) is a strong candidate if it were comprehensive. Since it is an 'update' and an 'announcement' of results, 'ER' (Earnings Release) is more appropriate than 'IR' (which implies the full report). The management change is secondary to the financial update in this context, although significant. I will classify it as an Earnings Release (ER) because it details period financial performance highlights, which is the core function of an ER. 9M 2023
2023-10-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.